Coutinho E M, Azadian-Boulanger G
Maternidade Climerio de Oliveira, Federal University of Bahia, Salvador, Brazil.
Fertil Steril. 1988 Mar;49(3):418-22. doi: 10.1016/s0015-0282(16)59765-9.
The effectiveness and acceptability of gestrinone administered by vaginal route was evaluated in a group of 110 patients with endometriosis. Patients were divided into four groups. The first three groups were treated by vaginal route. Group I (n = 17) received two 2.5-mg tablets weekly; group II (n = 31) received three 2.5-mg tablets weekly; group III (n = 35) received two 5.0-mg tablets weekly. Group IV consisted of 27 patients who received 2.5 mg of gestrinone orally twice weekly. Ninety-eight women completed the 6- to 8-month treatment period. Amenorrhea developed in all treatment groups, including group I (34%). The disappearance of both dyspareunia and dysmenorrhea occurred in most patients in all treatment groups soon after the second month of therapy. Patients treated by vaginal route had significantly less seborrhea and acne than those treated by oral route. Weight gain was also significantly less in vaginally treated women than in those treated orally. Pregnancy rate following discontinuation was not significantly different for the various groups.
在一组110例子宫内膜异位症患者中评估了经阴道途径给予孕三烯酮的有效性和可接受性。患者被分为四组。前三组采用经阴道途径治疗。第一组（n = 17）每周服用两片2.5毫克片剂；第二组（n = 31）每周服用三片2.5毫克片剂；第三组（n = 35）每周服用两片5.0毫克片剂。第四组由27例患者组成，他们每周口服两次2.5毫克孕三烯酮。98名女性完成了6至8个月的治疗期。所有治疗组均出现闭经，包括第一组（34%）。在治疗的第二个月后不久，所有治疗组的大多数患者的性交困难和痛经均消失。经阴道途径治疗的患者的皮脂溢和痤疮明显少于经口服途径治疗的患者。经阴道治疗的女性的体重增加也明显少于经口服治疗的女性。停药后的妊娠率在各治疗组之间无显著差异。
